Search
forLearn
5 / 801 resultslearn Finasteride
Frontline, gold standard treatment for combatting androgenic alopecia
learn Adenosine
nucleoside used for hair regrowth stimulant properties
learn Alfatradiol
a synthetic estrogen used topically as an anti-androgen
learn Dutasteride
Heavy duty finasteride that comes with higher risks, but scalp injections seem safe and are gaining popularity
Research
5 / 1000+ results
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
New treatments for hair loss show promise but need more testing for effectiveness and safety.
research Engineering MMP9-Responsive Antioxidative Micelle-Hydrogel Dressings for Sequential Inflammatory Remodeling and Pro-Angiogenesis in Diabetic Wound Healing
The hydrogel dressing RD@PVA helps heal diabetic wounds by reducing stress and improving blood vessel growth.
research A Randomized, Multicenter, Evaluator-blind Study to Evaluate the Safety and Effectiveness of VYC-12L Treatment for Skin Quality Improvements
VYC-12L effectively improves skin smoothness, reduces fine lines, and boosts hydration.
research Fabrication of polyvinyl pyrrolidone-K90/Eudragit RL100-based dissolving microneedle patches loaded with alpha-arbutin and resveratrol for skin depigmentation
Microneedle patches with alpha-arbutin and resveratrol can effectively reduce skin pigmentation without irritation.
research Bioadhesive Polydopamine-Vitamin A Derivative Hydrogels Reprogram the Wound Microenvironment for Scarless Wound Healing and Hair Follicle Regeneration
The hydrogel helps wounds heal without scars and promotes new hair growth.
Community Join
5 / 47 resultscommunity Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
community I’m taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.